March 30 (Bloomberg) -- Heart stents made by BostonScientific Corp., the world’s biggest seller of the artery-clearing devices, were less effective in studies than those fromAbbott Laboratories, Johnson & Johnson and Medtronic Inc. Taxus Liberte, Boston Scientific’s newest stent, requiredmore repeat ...Read More
* FDA inspection was at Mounds View, Minn., facility * Medtronic to answer warning letter in 15 days * Has taken some actions to address FDA concerns * Shares down 51 cents to $39.69 (Adds detail, updates shares) CHICAGO, Nov 18 (Reuters) - Medtronic ...Read More
(Corrects to show that the the Mounds View, Minn. facility is aunit headquarter, not a manufacturing plant) * FDA inspection was at Mounds View, Minn., facility * Medtronic to answer warning letter in 15 days * Has taken some actions to address FDA ...Read More
(Updates with details on FDA letter, Medtronic comments, updated share price) The U.S. Food and Drug Administration has issued a warning letter to Medtronic Inc.'s (MDT) big heart-rhythm device unit detailing issues the agency found at that businesses' corporate headquarters in ...Read More
* FDA inspection was at Mounds View, Minn., plant * Medtronic to answer warning letter in 15 days * Has taken some actions to address FDA concerns * Shares down 12 cents at $40.08 CHICAGO, Nov 18 (Reuters) - Medtronic Inc. (MDT.N) said onWednesday ...Read More
NATICK - Dr. Donald Baim, a renowned cardiologist and medical device executive, died yesterday following surgery to treat a form of cancer, his family said in a statement. He was 60. Dr. Baim had undergone recent surgery to remove diseased tissue ...Read More
NATICK, Mass (AP) - Dr. Donald Baim, a renowned cardiologist and medical device executive, died Friday following surgery to treat a form of cancer, his family said in a statement. He was 60. Baim had undergone recent surgery to remove diseased ...Read More
NATICK, Mass—Dr. Donald Baim, a renowned cardiologist and medical device executive, died Friday following surgery to treat a form of cancer, his family said in a statement. He was 60. Baim had undergone recent surgery to remove diseased tissue caused by ...Read More
Boston Scientific Corp. will pay $296 million in an agreement with the Justice Department stemming from an investigation into problems with Guidant Corp. defibrillators and a major related recall in 2005. Boston Scientific has been addressing fallout from those problems since ...Read More
Nov. 6 (Bloomberg) -- Boston Scientific Corp. agreed to pay$296 million to settle a U.S. Justice Department investigationinto the device maker’s Guidant subsidiary and restated third-quarter results to show a loss. Guidant will plead to two misdemeanor charges related tofailures to ...Read More
Boston Scientific Corp. (BSX) agreed to pay $296 million to resolve a JusticeDepartment investigation into to product advisories at its Guidant defibrillatorunit. Shares of the medical-device maker fell 3.1% at $7.80 in premarket trading.Through Thursday, the stock was up 4% for ...Read More
CHICAGO (Reuters) - Medical device maker Boston Scientific Corp (BSX.N) reached an agreement with the U.S. Department of Justice related to product recalls issued by its Guidant subsidiary, and will record a third-quarter charge of $294 million, the company said ...Read More
Medical device maker ">Boston Scientific in Natick said today it received European marketing approval for its latest drug-coated stent technology, which prevents blocked arteries. The company said it will begin marketing its Promus Element stent in the European Union immediately. The ...Read More
U.S. stocks posted their first weekly decline in three weeks as several major companies forecast earnings that trailed Wall Street estimates. Boeing slid 6.2 percent, the steepest drop among companies in the Dow Jones industrial average, as it posted a loss ...Read More
* Cuts full-year profit target, citing weak ICD market * Shares fall 6.6 percent in post-market trading (Adds analyst comments, earnings details, byline) CHICAGO, Oct 19 (Reuters) - Boston Scientific Corp (BSX.N)on Monday reported a quarterly net profit, compared with ayear-ago loss, ...Read More
Boston Scientific Corp. swung to a third-quarter profit from a charge-laden loss a year earlier, but sales grew less than Wall Street expected amid some softness in the market for heart-rhythm devices. Boston Scientific's report closely follows a weak preliminary third-quarter ...Read More
CHICAGO (Reuters) - Boston Scientific Corp (BSX.N) on Monday reported a quarterly net profit, compared with a year-ago loss, but cut its full-year earnings outlook, citing weakness in the market for implantable heart defibrillators. The company's shares fell 6.6 percent to ...Read More
Oct. 19 (Bloomberg) -- Boston Scientific Corp. reported athird-quarter profit on higher sales of cardiac stents and heartrhythm devices, topping analysts’ estimates. The company loweredits 2009 forecast. Net income of $200 million, or 13 cents a share, comparedwith a loss of ...Read More
Boston Scientific Corp. (BSX) swung to a third-quarter profit as the company recorded a small revenue increase and much smaller unusual charges. However, the medical-device maker lowered its earnings outlook for the year, despite boosting its revenue target. The company now ...Read More
ST. LOUIS — A committee at Washington University did not find sufficient evidence that researcher Timothy Kuklo falsified a study, but said he had violated two school policies in his work. Kuklo took leave in May and resigned in September after ...Read More
ST. LOUIS (AP) - A committee at Washington University did not find sufficient evidence that researcher Timothy Kuklo falsified a study, but said he had violated two school policies in his work. Kuklo took leave in May and resigned in September ...Read More
